Takeaways: Siliq’s listing under Alberta’s public drug plan expands brodalumab’s public coverage across Canada, leaving only British Columbia without provincial reimbursement and improving...
Takeaways: Knight Therapeutics’ Canadian launch of WYNZORA strengthens its dermatology portfolio and marks the commercialization of a product it inherited through the Paladin acquisition. The launch a...
Takeaways: Zasocitinib’s Phase 3 win over deucravacitinib suggests it could become a best-in-class oral TYK2 option for moderate-to-severe plaque psoriasis if regulators...
